Tools for Practice Outils pour la pratique

#334 Wouldn’t Bet On it: What is the risk of muscle symptoms on statins?

What are the effects of statins on muscles?

Statins increase the risk of muscle symptoms (includes pain, cramps, and weakness) in their first year of use, from 14% (placebo) to 14.8%, but are similar to placebo after 1 year. When patients report muscle symptoms, only 1 in 15 is due to the statin. Statins may increase muscle symptoms with creatine kinase rise 10x normal for 1 in ~3000 patients over placebo.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

  • 7 systematic reviews [11-135 randomized controlled trials (RCTs); 18,192-192,977 patients] from the last 5 years.1-7 Focusing on the most recent (23 RCTs; 154,664 patients x4.3 years).1 Results statistically significant unless indicated.
    • Any muscle symptoms, statin versus placebo,
      • Anytime: 27.1% versus 26.6% (placebo).1
        • Within 1st year: 14.0% versus 14.8%, number needed to harm=125.
        • After 1st year: 14.8% versus 15.0% (not statistically different).
      • Other systematic reviews2-7 similar but not statistically different for myalgia,5 ≥65 age subgroup,4 or intensity subgroups versus placebo.2
      • No difference by statin type,3 lipophilic/hydrophilic statin,6 or age groups.1,5,6
    • Any muscle symptoms, more versus less-intense statin:
      • Any timepoint: 36.1% versus 34.8% (less intense).1
      • Other systematic reviews found similar.2
    • Creatine kinase >10x upper limit of normal (myopathy): 077% versus 0.044% (placebo).1
      • 4 other systematic reviews:2-5 No difference.
      • More versus less-intense statin:1,2 Results no different for approved statins/doses (excluding simvastatin 80mg).
    • Rhabdomyolysis:
      • 3 systematic reviews: 4,5 No difference.
    • Discontinuation for muscle symptoms2,4 or any adverse event4,5,7 not statistically increased.
  • Three n-of-1 trials (8-200 patients, previous statin intolerance due to muscle symptoms) randomized to 3-4 cycles of ~3-8 weeks of statin,8-10 placebo,8-10 and no-pill8 Muscle symptom scores:
    • Statin versus placebo:8-10 no difference.
    • Statin versus no-pill:8 16 versus 8 (no-pill) (scale=0-100, higher worse).

  • Mean creatine kinase rise1 with statin therapy ~2%.
  • Events like myopathy and rhabdomyolysis are too infrequent to discern statin effects in meta-analysis of >100,000 RCT participants.
    • Statin-induced rhabdomyolysis estimated at 2-3 excess cases/100,000 patient-years.11
  • Guidelines recommend:
    • In patients with non-severe muscle-symptoms, offer retrial of same or lower-intensity statin.12
    • Monitoring creatinine kinase is generally not encouraged, but check if symptoms or high-risk.12,13

Evelyn Westen February 22, 2023

My understanding of this topic is confirmed- nice article to share wiht patients with questions

Evelyn Westen February 22, 2023

short , concise article to share with patients with questions

Brigit Swenson February 22, 2023

Would have been nice to show reminder of “more intense” statins vs less intense

Justine Stewart February 26, 2023

this confirmed what I have found in my practice in the past few years- I started asking patients to note their baseline sx’s of muscle aches/cramps before they start a statin, and the number who report increased muscle aches/pains after starting the statin is significantly decreased compared with my previous practice of discussing myalgia as potential adverse effect but not asking the patient to note their pre medication baseline of myalgia before starting the statin

Mark Sorestad March 2, 2023

great review of evidence, will be helpful in counselling patients who are google experts on the subject of statin side effects!

Adriana Hajas March 4, 2023

good synopsis of studies

Janette Hurley February 5, 2024


Latest Tools for Practice
Derniers outils pour la pratique

#369 Remind me, do medications that target brain amyloid improve my dementia?

Are amyloid-targeting monoclonal antibodies safe and effective for mild cognitive impairment or Alzheimer’s dementia?
Read Lire 0.25 credits available Crédits disponibles

#368 Sodium Restriction in Heart Failure: Beneficial or pouring salt in the wound?

Does sodium restriction improve outcomes in patients with chronic heart failure?
Read Lire 0.25 credits available Crédits disponibles

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Jamie Falk BSc(Pharm) PharmD
  • Allison Paige MD CCFP
  • G. Michael Allan MD CCFP

1. Cholesterol Treatment Trialist Collaboration. Lancet 2022; 400:832-45.

2. Davis JW, Weller SC. BMJ Open 2021; 11:e043714. doi:10.1136/bmjopen-2020-043714.

3. Cai T, Abel L, Langford O, et al. BMJ 2021; 374:n1537.

4. Zhou Z, Albarqouni L, Curtis AJ, et al. Drugs & Aging 2020; 37:175–185.

5. Chou R, Cantor A, Dana T, et al. JAMA. 2022; 328:754-771. doi:10.1001/jama.2022.12138

6. Irwin JC, Khalesi S, Fenning AS, et al. Pharmacol Res 2018; 128:264-73.

7. Yebyo HG, Aschmann HE, Kaufmann M, et al. Am Heart J 2019; 210:18-28.

8. Wood FA, Howard JP, Finegold JA, et al. N Eng J Med Nov 15, 2020 doi: 10.1056/NEJMc2031173

9. Joy TR, Monjed A, Zou GY, et al. Ann Intern Med. 2014; 160:301-310.

10. Herrett E, Williamson E, Brack K, et al. BMJ 2021; 372:n135.

11. Collins R, Reith C, Emberson J, et al. Lancet. 2016 Nov 19; 388(10059):2532-2561.

12. Allan GM, Lindblad AJ, Comeau A et al. Can Fam Physician 2015; 61(10):857-67, e439-50.

13. Grundy SM, Stone NJ, Bailey AL, et al. J Am Coll Cardiol. 2019; 73(24):3168-209.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.